USA flag logo/image

An Official Website of the United States Government

Antisense Morpholino Oligomers to Treat Retinopathy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65566
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
EY015014
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Avi Biopharma, Inc.
Avi Biopharma, Inc. 4575 Sw Research Way, Ste 200 Corvallis, OR 97333 0106
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Antisense Morpholino Oligomers to Treat Retinopathy
Agency: HHS
Contract: 1R43EY015014-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): The broad, long-term objectives of the application are to develop antisense inhibitors of retinopathy and document their mechanism(s) of action. Retinopathy is a significant cause of eye disease and has a major impact on development, learning, communicating, working, health, and quality of life for affected individuals. This application focuses on the inhibition of retinal neovascularization using antisense oligomers directed against endothelial cell alphav integrins, using a mouse model of retinopathy of prematurity. Alphav integrins are highly up-regulated during angiogenesis, and pharmacologic inhibitors of alphav integrins prevent angiogenesis in vivo. Whereas small organic molecules, synthetic peptides, and monoclonal antibodies have been used in the past to inhibit av integrin function, this application proposes to use antisense oligomer inhibition of alphav integrin expression. Preliminary studies show that antisense oligomers directed against integrin alphav inhibit retinal neovascularization in mice in a sequence-specific manner. Furthermore, the specificity of antisense oligomers holds the promise of minimal side-effects compared to previous pharmacologic inhibitors. The specific aims are: I - To identify an alphav antisense oligomer sequence that effectively inhibits translation of human and mouse av integrin. II - To identify an optimal dose and route of administration of the alphav antisense PMO identified in Aim I that effectively inhibits neovascularization in the retina of ROP mice. This will be achieved by screening a series of antisense phosphorodiamidate morpholino oligomers using in vitro alphav translation assays and an in vivo mouse model of retinopathy of prematurity. The primary goal of this grant is to identify the optimal antisense alphav PMO, dose and schedule that maximally decreases alpha V expression and inhibits retinopathy of prematurity.

Principal Investigator:

Gayathri R. Devi
5417533635
GRDEVI@AVIBIO.COM

Business Contact:

Mark Webber
5417533635
MWEBBER@AVIBIO.COM
Small Business Information at Submission:

AVI BIOPHARMA, INC.
AVI BIOPHARMA, INC. 4575 SW RESEARCH WAY, STE 200 CORVALLIS, OR 97333

EIN/Tax ID: 930797222
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No